Repligen (RGEN) Appoints New R&D SVP
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Repligen Corporation (Nasdaq: RGEN) announced the appointment of Ralf Kuriyel to the position of Senior Vice President of Research & Development (R&D). Mr. Kuriyel was most recently Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation (Pall), a global leader in the high-tech filtration, separation and purification markets, whose acquisition by Danaher Corporation was completed in August 2015. During his 11-year tenure at Pall, Mr. Kuriyel played a key role in expanding the Global Applications R&D function to include cell culture and single-use applications, process monitoring technologies, and process development services. Prior to Pall, Mr. Kuriyel held various technology and applications development management roles within the bioprocess and biopharm divisions of Millipore Corporation (Millipore), which was acquired by Merck KGaA in 2010. Mr. Kuriyel will take over from Dr. James Rusche, who is retiring at the end of this year following a distinguished 30-year career with the Company.
At Repligen, Mr. Kuriyel will lead Repligen’s development efforts and influence the strategic direction of the Company’s product portfolio as a core member of a cross-functional team. His responsibilities include overseeing the development of new and innovative products and services for applications within biomanufacturing, building on Repligen’s record of excellence in upstream filtration and downstream purification technology as well as its commitment to customization and convenience for end users.
Tony J. Hunt, President and Chief Executive Officer of Repligen said, “We’re very pleased to welcome Ralf to Repligen, where his combined 30 years of bioprocess technology development experience with Pall and Millipore compliments and builds upon the high caliber of our R&D organization. Ralf will be an important contributor as the Company continues on a path of growth and innovation based on anticipating and responding to the evolving needs of our biopharmaceutical manufacturing customers, particularly in the areas of flexible and continuous processing technologies.”
Mr. Kuriyel received his B.S. and M.S. in Chemical Engineering from Rensselaer Polytechnic Institute, and completed coursework for the Tufts University Ph.D. program in Chemical Engineering. He is an inventor of multiple patents and has co-authored over thirty scientific publications pertaining to bioprocessing - including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Perma-Fix (PESI) Names S. Robert Cochran to Board of Directors
- Ethicon Announces Acquisition of Megadyne Medical Products (JNJ)
- Minerva Neurosciences (NERV) Reports Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!